9-Fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-(tricyclo(3.3.1.13,7)dec-1-ylformate) | 40242-27-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 9-Fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-(tricyclo(3.3.1.13,7)dec-1-ylformate)
• 英文别名: [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] adamantane-1-carboxylate
• CAS: 40242-27-1
• 化学式: C₃₃H₄₃FO₆
• 分子量: 554.7
• InChiKey: NNYUDLQXONVMAY-VDOFVVGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  40
• 可旋转键数：
  5
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Sustained release eye drop formulations
  申请人：Ramscor, Inc.

  公开号：US10744202B2

  公开（公告）日：2020-08-18

  This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably α-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.

  本发明提供了生物相容性、可生物降解的滴眼液药物制剂，可用于治疗眼部疾病。特别是，生育酚及其低水溶性酯类，尤其是 α-生育酚乙酸酯，是生物相容性、无刺激性、可持续释放活性剂的外用眼药水制剂的理想载体。
• Inhalable formulation of a solution containing a tiotropium salt
  申请人：——

  公开号：US20020137764A1

  公开（公告）日：2002-09-26

  A liquid, propellant-free pharmaceutical preparation comprising: (a) a first active substance comprising a tiotropium salt, in a concentration based on tiotropium of between 0.0005% and 5% by weight; (b) a second active substance selected from the group consisting of: an antiallergic, antihistamine, steroid, and leukotriene antagonist; (c) a solvent selected from water or a water/ethanol mixture; and (d) a pharmacologically acceptable preservative, wherein the pH of the preparation is adjusted to between 2.0 and 4.5 with an acid and the tiotropium salt is dissolved in the solvent, optionally including a pharmacologically acceptable complexing agent, stabilizer, a pharmacologically acceptable cosolvent, or other pharmacologically acceptable adjuvants and additives; a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler, and a method of treating asthma or COPD in a patient using the pharmaceutical preparation.

  一种不含推进剂的液体药物制剂，包括 (a) 第一种活性物质，包括噻托溴铵盐，噻托溴铵的浓度为 0.0005%至 5%（按重量计）； (b) 第二种活性物质，选自由抗过敏剂、抗组胺剂、类固醇和白三烯拮抗剂组成的 组； (c) 选自水或水/乙醇混合物的溶剂；以及 (d) 药理学上可接受的防腐剂、 其中制剂的 pH 值用酸调节到 2.0 至 4.5 之间，噻托溴铵盐溶解在溶剂中、 可选地包括药理学上可接受的络合剂、稳定剂、药理学上可接受的共溶剂或其他药理学上可接受的佐剂和添加剂；一种通过在吸入器中雾化药物制剂来给药的方法，以及一种使用该药物制剂治疗患者哮喘或慢性阻塞性肺病的方法。
• Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage
  申请人：Hochrainer Dieter

  公开号：US20050159441A1

  公开（公告）日：2005-07-21

  The invention relates to an apparatus comprising a closure-cap and a container in the form of a two-chamber cartridge in which an active ingredient and a solvent can be stored separately until the apparatus is used in a nebuliser, as well as an active substance concentrate in which the active-substance is present as a solution or suspension for storage purposes.

  本发明涉及一种装置，包括一个封盖和一个容器，容器为双室筒状，其中的活性成分和溶剂可以分开储存，直到该装置用于雾化器，还涉及一种活性物质浓缩物，其中的活性物质以溶液或悬浮液的形式存在，以便储存。
• Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols
  申请人：Freund Bernhard

  公开号：US20060127322A1

  公开（公告）日：2006-06-15

  The invention relates to ethanol-containing pharmaceutical preparations for the production of propellant-free aerosols.

  本发明涉及用于生产无推进剂气雾剂的含乙醇药物制剂。
• Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers
  申请人：Kuehn Torsten

  公开号：US20060157054A1

  公开（公告）日：2006-07-20

  The present invention relates to capsules for housing pharmaceutical preparations for powder inhalers with increased medicinal product safety and capsules for pharmaceutical preparations for powder inhalers with improved adaption to use in powder inhalers. The capsules consist of non-water-soluble, hydrophobic plastics, which themselves do not substantially influence the pharmaceutical quality of the contents, but improve the usability of the filled capsules in respect of their operation, the period of use and/or the geographical location of their use and are advantageous in various steps from manufacture to use.

  本发明涉及用于容纳粉末吸入器药物制剂的胶囊，具有更高的药用产品安全性，以及用于容纳粉末吸入器药物制剂的胶囊，具有更好的粉末吸入器使用适应性。这些胶囊由非水溶性疏水性塑料组成，其本身不会对内容物的药用质量产生实质性影响，但在操作、使用期限和/或使用地理位置方面提高了灌装胶囊的可用性，并在从生产到使用的各个步骤中具有优势。